BNP Paribas Financial Markets Buys 20,579 Shares of Qiagen N.V. $QGEN

BNP Paribas Financial Markets grew its stake in shares of Qiagen N.V. (NYSE:QGEN) by 1.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,179,437 shares of the company’s stock after acquiring an additional 20,579 shares during the quarter. BNP Paribas Financial Markets owned about 0.56% of Qiagen worth $53,039,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of QGEN. Johnson Investment Counsel Inc. lifted its position in shares of Qiagen by 0.4% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock worth $2,563,000 after buying an additional 240 shares during the last quarter. Allworth Financial LP lifted its position in shares of Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after buying an additional 256 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Qiagen by 0.5% during the 3rd quarter. Bessemer Group Inc. now owns 51,780 shares of the company’s stock worth $2,288,000 after buying an additional 262 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in shares of Qiagen by 1.8% during the 4th quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after buying an additional 290 shares during the last quarter. Finally, Truist Financial Corp lifted its position in shares of Qiagen by 4.1% during the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock worth $379,000 after buying an additional 331 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on QGEN shares. TD Cowen restated a “hold” rating and set a $40.00 price objective (down from $46.00) on shares of Qiagen in a research report on Thursday, May 7th. Weiss Ratings downgraded Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. UBS Group set a $52.00 price objective on Qiagen in a research report on Monday, February 9th. Citigroup restated a “hold” rating on shares of Qiagen in a research report on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their price objective on Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $44.98.

Qiagen Price Performance

Qiagen stock opened at $35.72 on Wednesday. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $7.36 billion, a PE ratio of 18.65, a P/E/G ratio of 3.60 and a beta of 0.66. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The stock has a 50-day moving average price of $37.60 and a two-hundred day moving average price of $44.67.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period last year, the company earned $0.56 earnings per share. Analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. Qiagen’s payout ratio is currently 13.61%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.